Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
opn-7486
- Development stage
- Phase 1
- Lead developer
- Opna Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OPN-7486 is an orally administered small molecule dual inhibitor targeting colony stimulating factor 1 receptor (CSF1R) and tropomyosin receptor kinase (TRK) family members. By inhibiting CSF1R, OPN-7486 blocks the recruitment and infiltration of tumor-associated macrophages (TAMs), which are known to promote tumor growth through immune suppression in the tumor microenvironment. The drug also inhibits TRK receptors (TrkA, TrkB, TrkC), which are implicated in oncogenic signaling pathways. Developed for oncology indications, OPN-7486 is currently in Phase 2 clinical trials for cancer. It was originally developed by Plexxikon and is now being advanced by Opna Bio[1][2][3][5][7].
- Other names
- OPN 7486OPN7486OPN-7486PLX-7486PLX7486PLX 7486
02
Targets
NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)NTRK1 (Tropomyosin-related receptor kinase A)CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on opn-7486.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on opn-7486.